NCT07171528 2025-09-12
KOV-02S
National Cancer Center, Korea
Phase 2 Recruiting
Clinical Trials
11 trialsNCT06839144 2025-07-11
OC-POP-PT
Tel-Aviv Sourasky Medical Center
Phase 2 Recruiting
NCT05200260 2025-02-10
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Shanghai Gynecologic Oncology Group
Phase 2 Recruiting
NCT05753826 2024-02-06
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Fujian Cancer Hospital
Phase 2 Recruiting
NCT04519151 2023-06-08
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
Phase 2 Recruiting
NCT05597527 2022-10-28
Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT03942068 2019-05-08
Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03412526 2019-04-04
Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian
Sheba Medical Center
Phase 2 Unknown
NCT03547375 2018-06-06
Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy
Anhui Provincial Hospital
Phase 2 Unknown
NCT01669226 2016-12-19
AICE
Shanghai Gynecologic Oncology Group
Phase 2 Completed
NCT02595021 2016-07-26
Total/Subtotal Colectomy in Ovarian Cancer
Shanghai Gynecologic Oncology Group
Phase 2 Unknown